An ongoing phase I/II clinical trial (NCT03374657) is examining the safety, tolerability, and efficacy of subretinal administration of AAV8-RLBP1 (CPK850) in patients with RLBP1-RP, though no data are yet available. The gene discussed is RLBP1; the disease is retinitis pigmentosa 1.